LivaNova Surges in Q3 2026 as Tech Innovations Offset Legacy Legal Headwinds

GLOUCESTER, England – November 04, 2026 – LivaNova PLC reported a robust third quarter for 2026, delivering net revenue of $393.1 million, a 9.9% increase on a reported basis and a 10.0% jump in constant currency compared to the prior year. The medical technology giant, known for its cardiac and neurological solutions, also raised its full-year revenue and earnings guidance, signaling deep confidence in its core commercial portfolio. However, underneath the double-digit operational growth lies a complex financial narrative, as the company continues to navigate the heavy drag of historical environmental and product liability litigation.

“Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy technologies,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “We also made meaningful progress against key milestones, positioning us to address significant market demand while expanding patient access to care.”

Behind the upbeat executive sentiment is a tale of two balance sheets. While the enterprise is rapidly expanding its footprint in operating rooms and sleep clinics worldwide, its statutory profitability remains heavily encumbered by legacy issues, creating a stark contrast between its operational triumphs and its bottom-line realities.

Cardiopulmonary Powerhouse: Essenz and Oxygenator Expansion

LivaNova’s Cardiopulmonary segment remains the undisputed engine of its top-line acceleration. In the third quarter, the division posted $225.3 million in revenue, representing a 10.9% increase across all regions. This surge is primarily fueled by the accelerating adoption of the Essenz Perfusion System and an insatiable global demand for single-use surgical consumables.

The Essenz Perfusion System, which received U.S. Food and Drug Administration (FDA) 510(k) clearance in March 2023, has rapidly become a cornerstone of modern cardiac surgery. Designed to optimize clinical workflows and enhance patient care during cardiopulmonary bypass procedures, the next-generation heart-lung machine has already supported over 100,000 patients globally. With an estimated 70% market share in heart-lung machines and an installed base of approximately 7,000 units worldwide, the manufacturer is successfully defending its dominance against formidable rivals like Terumo Corporation and Medtronic.

To capitalize on this momentum, LivaNova announced that it has achieved operational production on a newly constructed oxygenator manufacturing line. This represents a critical infrastructure milestone. As the global oxygenators market—driven by an aging population and rising cardiovascular disease rates—marches toward a projected $435.2 million valuation by 2033, supply chain resilience has become a major competitive differentiator.

"Securing a robust domestic and international supply of membrane oxygenators is paramount for hospital procurement teams right now," noted an independent medical device supply chain analyst. "By expanding manufacturing capacity, LivaNova is directly addressing the surgical backlog and consumable shortages that have plagued healthcare systems since the pandemic."

Challenging the Sleep Apnea Monopoly

While cardiopulmonary tech provides the financial bedrock, the Neuromodulation unit—which grew 11.1% to $166.1 million in Q3—is charting the organization's most disruptive future path. A major regulatory victory arrived in October 2026 when the American Medical Association (AMA) CPT Editorial Panel established new Category I Current Procedural Terminology (CPT) codes for the company's proximal hypoglossal nerve stimulation (pHGNS) therapy.

Effective January 1, 2028, these codes will standardize billing and reimbursement for the treatment of moderate to severe obstructive sleep apnea (OSA). This effectively clears the runway for the device maker to directly challenge Inspire Medical Systems, which has largely monopolized the OSA neurostimulation market over the last decade.

Entry into this arena is powered by the aura6000 System, which secured FDA Premarket Approval in March 2026. The clinical data backing the device is formidable. The OSPREY randomized controlled trial demonstrated that 65% of patients were classified as responders at 12 months, with a median 68% reduction in the Apnea-Hypopnea Index (AHI).

Crucially, the aura6000 System bypasses two major hurdles that currently limit patient access to competing devices. It is the first and only hypoglossal nerve stimulation device approved in the U.S. without a contraindication for complete concentric collapse (CCC) and without the requirement for a pre-implantation drug-induced sleep endoscopy (DISE).

"Removing the DISE requirement fundamentally changes the patient funnel," explained a clinical neurologist familiar with the OSPREY trial data. "It reduces preoperative friction, lowers costs, and broadens the eligible patient population. When the Category I codes activate in 2028, we expect to see a significant shift in how sleep clinics prescribe neurostimulation."

Engineers are also preparing to launch a next-generation, MRI-compatible version of the aura6000 System featuring a 15-year rechargeable battery in the first half of 2027, further intensifying the impending market clash.

Operational Surge vs. Legacy Headwinds

Despite these commercial and clinical triumphs, the third-quarter earnings report reveals a stark divergence between GAAP and non-GAAP profitability. On a U.S. GAAP basis, third-quarter diluted earnings per share (EPS) plummeted to $0.11, down from $0.49 in the same period last year. Conversely, adjusted diluted EPS—which strips out one-time charges and legal provisions—climbed to $1.23, up from $1.11.

This $1.12 per-share gap underscores the massive financial weight of legacy liabilities. The corporation continues to battle product liability lawsuits surrounding its 3T Heater-Cooler device, which has been linked to the spread of Mycobacterium chimaera bacteria during open-heart surgeries. Just recently, a Kansas jury awarded $7.65 million in a contamination case, assigning 12% of the fault to LivaNova. The ongoing legal defense costs and settlement provisions consistently erode statutory operating income.

Even more daunting is the $383.6 million environmental liability sitting on the balance sheet related to SNIA S.p.A., a former parent company of the Sorin Group. Following a March 2025 ruling by the Italian Supreme Court, LivaNova was held liable for historical environmental damages, forcing the business to record a massive provision. While executives are actively contesting additional costs suggested by the Italian Ministry of Environment and maintain they have sufficient resources to satisfy the current liability, the SNIA overhang—alongside a separate $41.8 million provision for environmental remediation at the Saluggia site—remains a persistent drain on investor sentiment.

Yet, the strength of the underlying business appears robust enough to absorb these shocks. Driven by the success of the Essenz rollout and the burgeoning neuromodulation pipeline, LivaNova raised its full-year 2026 revenue growth guidance by 100 basis points to a range of 9% to 10% on a constant-currency basis. Management also bumped the adjusted diluted EPS target to between $4.40 and $4.50.

For the broader medical technology sector, this third-quarter performance serves as a masterclass in compartmentalization. The organization is simultaneously managing the costly ghosts of its corporate past while aggressively engineering its future, betting that breakthrough innovations in the operating room and the sleep clinic will ultimately outpace the gavel of the courtroom.